Plants as Sources of Natural and Recombinant Antimalaria Agents

Peyman Habibi1 · Yao Shi2 · Maria Fatima Grossi-de-Sa4,5,6 · Imran Khan3

Received: 7 November 2021 / Accepted: 8 April 2022 / Published online: 29 April 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract
Malaria is one of the severe infectious diseases that has victimized about half a civilization billion people each year worldwide. The application of long-lasting insecticides is the main strategy to control malaria; however, a surge in antimalarial drug development is also taking a leading role to break off the infections. Although, recurring drug resistance can compromise the efficiency of both conventional and novel antimalarial medicines. The eradication of malaria is significantly contingent on discovering novel potent agents that are low cost and easy to administer. In this context, plant metabolites inhibit malaria infection progression and might potentially be utilized as an alternative treatment for malaria, such as artemisinin. Advances in genetic engineering technology, especially the advent of molecular farming, have made plants more versatile in producing protein drugs (PDs) to treat infectious diseases, including malaria. These recent developments in genetic modifications have enabled the production of native pharmaceutically active compounds and the accumulation of diverse heterologous proteins such as human antibodies, booster vaccines, and many PDs to treat infectious diseases and genetic disorders. This review will discuss the pivotal role of a plant-based production system that expresses natural antimalarial agents or host protein drugs to cure malaria infections. The potential of these natural and induced compounds will support modern healthcare systems in treating malaria infections, especially in developing countries to mitigate human fatalities.

Keywords Medicinal plants · Malaria · Vaccine · Genetic engineering · Molecular farming

Introduction
Malaria is among the deadliest infectious diseases caused by Plasmodium parasites. Malarial infections are transmitted within the population through infected female Anopheles mosquitoes. Five parasite species including P. knowlesi, P. ovale, P. malariae, P. vivax, and P. falciparum are known sources of malaria in humans, and the two last species pose the greatest threat [1] as P. vivax causes the most morbidity and P. falciparum causes most mortality, mainly in children under five [2]. Malaria has affected around half of the modern civilization and is endemic in more than hundred countries [3]. The malaria-related mortalities are disproportionately high in developing countries compared to technologically advanced countries due to several reasons. Unfortunately, the socioeconomic status of the population in developing countries has limited their access to antimalaria therapies. According to the world malaria report released in December 2019, approximately 228 million malaria cases have occurred worldwide, of which 435,000 malaria-related deaths have occurred in African regions where 85% of global malaria cases and 94% of deaths were reported [4]. Considering this, current predictions suggest that nearly half of the world’s inhabitants are at high risk of malaria infections. In addition to increasing deaths, malaria infections can account for massive economic losses, with an estimated US$2.7 billion in healthcare-related...
expeditures in 2018 [4], subsequently contributing to economic deterioration in resource-poor countries.

The current pandemic of SARS-CoV-2, known as COVID-19, can potentially trigger malaria crises in the region because of the vulnerability of health and economic systems, along with the high burden of malaria [5]. Moreover, the potential impact of the spread of COVID-19 on Plasmodium falciparum malaria morbidity and mortality has been reported [6], and World Health Organization (WHO) has strongly highlighted the importance of continuing malaria diagnostic, prevention, and case management activities [7]. Keeping in view the urgency of novel therapeutics, plants can offer natural and recombinant medication to combat widespread malaria infections. Since malaria is commonly associated with poverty, inexpensive large-scale production of antimalaria drugs under the current infrastructure in the remote area is an urgent need for its eradication. This goal can be achieved efficiently in a cost-effective manner by bulk production of antimalaria drugs using a plant expression system by avoiding the obligatory cold chain conditions for its storage and distribution. Hence, this review also elaborates on the capacity of herbal medicine and plant molecular farming to treat malaria infections keeping the developing world in focus.

**Malaria Life Cycle**

The life cycle of the malarial parasite included multiple stages that involve two hosts, i.e., the human and the mosquito. The life cycle initiates with a single bite of infected female Anopheles mosquitoes and inoculation of uninucleated sporozoites into the bloodstream. Sporozoites subsequently migrate from blood to liver tissue in less than a minute and soon after five days, sporozoites develop into uninucleated merozoites with a range of 10,000–40,000 that further can invade a normal erythrocyte [8]. After maturation in the liver, merozoites can be released, and the cycle of intraerythrocytic-stage development, rupture, and reinvasion can be continued and/or can also be developed into sexual-stage parasites, gametocytes. In the mosquito’s gut, gametocytes separate from erythrocytes and produce gametes to complete the life cycle by fusing to form a zygote (ookinetes) which subsequently transform into an oocyst in which new sporozoites are formed. Finally, the newly produced sporozoites migrate to the salivary glands and eventually become infectious to humans when the mosquito feeds [9].

**Currently Available Antimalarial Drugs**

Malaria control and eradication are complicated where different factors affect the treatment process, such as drug resistance, socioeconomic status, cost of production, and drugs quality. Antimalarial therapy is currently based on four major drug classes, including quinolone derivatives, antifolates, artemisinin derivatives, and antimicrobial [10]. The most available drugs target the asexual phase (erythrocytic stage) of the malaria parasite generating symptomatic illness [11]. Despite intensive efforts in malaria research, currently, there is no report on identifying a single drug, which can wipe out all strains of malaria and appear in the global market. Moreover, single drugs utilization is limited to a certain period until the emergence of drug resistance. For example, malaria resistance to artemisinin derivatives was identified in Myanmar, Thailand, Cambodia, and Vietnam [12]. Hence, a combination of drugs has been suggested as an alternative to combat malaria infections. Changing the combination of drugs may decrease the risk of resistance development as well as treatment failure. In this context, depending on the severity of the disease, the geographic location of the infection and the species of parasites, antimalarial dosing therapies are prescribed accordingly [11].

In the case of artemisinin-resistant malaria, WHO recommends artemisinin-based combination therapy (ACT) as a reliable and genuine therapeutic antimalarial drug. However, the drug resistance was reported to multiple ACTs in Cambodia Pailin province; therefore, a combination without artemisinin (atovaquone plus proguanil) was suggested by WHO in 2013 [13]. In addition, artemoline is an antimalarial compound reported in the early 2000s marketed in India and African countries in fixed dose combination with piperaquine. However, the dose combination was not approved to date by WHO for general use [12]. In addition, comprehensive reviews of drug resistance and efficiency have been documented [14–16]. The general guidelines for the control and treatment of malaria by WHO were also provided [17]. The wealth of data is available where antimalarial drugs and potential drug candidates are reviewed [10, 18–21].

**Herbal Medicine Against Malaria**

Medicinal plants may play a critical role in synthesizing novel and potent antimalarial agents. Pharmacological studies have been performed on plant extracts, and purified metabolites for antimalarial activity have indicated the efficacy of most plants in the treatment of malaria. More importantly, there is no evidence of resistance because of the plant’s synergistic action of several constituents representing the great potential of plant extract against malaria resistance. Herbal medicine may also contribute to reduce the risks of disease without removing the continued exposure to infection necessary to retain immunity, which is critical in the management and eradication of malaria particularly in Africa [22]. Antimalarial compounds, including natural...
products and plant extracts have been reported in several review articles which are summarized in the following paragraphs.

The review by [23] evaluated the antimalarial activity of 124 medicinal plant species that belong to 55 families and 99 genera during 1991–2016 in Ethiopia. This review also assessed the antiplasmodial activity of 25 plant extracts with their structures and 28 medicinal plant species from 24 families commonly used for malarial treatment. *Allium sativum* L., *Croton macrostachyus Del.*, *Carica papaya* L., *Lepidium sativum* L., and *Vernonia amygdalina Del.* were reported plant species based on ethnomedical survey performed in this review and *A. sativum*, *L.* and *C*, *papaya* L., are reported based on traditional healers for treatment of malaria. Plant leaves are reported as most frequently used plant part, while alkaloids and terpenoids are reported as chemical classes most frequently identified for their antiplasmodial activity.

In another study, a total of 356 active chemical constituents from antimalarial plants are summarized by [24]. This review examined 26 active components with their chemical structures. The compounds listed in this review belong to the class of alkaloids, flavonoids, terpenoids, saponins, tannins, essential oils, sesquiterpene lactones, xanthanoids, polyphenol, iridoid glycosides, coumarins, anthaquinones, limonoids, tetranortriterpenoids, triterpenes, cembranolides, polyphenol, iridoid glycosides, coumarins, anthraquinones, coumarins, anthraquinones.

A large number of 2,000 plant extracts from 50 families against *P. falciparum* were studied and dozens of plants with antimalarial activity were discovered which cover a total of 175 antiplasmodial compounds extracted from plants from 2001 to the end of 2017. Twenty-five out of these 175 antiplasmodial compounds belong to marine plants. All these compounds are organized according to their plant family of origin. After screening of 175 antiplasmodial compounds, the activities of 171 compounds belonging to the alkaloid and terpenoid classes have been reviewed in the first and second sections, respectively. In vitro and in vivo assays of some derived phytochemicals also have been discussed. The cheminformatics analysis of > 500 natural products extracted from African flora have been reviewed [27, 28].

The activities of 171 compounds belonging to the alkaloid and terpenoid classes have been reviewed in the first and second sections, respectively. In vitro and in vivo assays of some derived phytochemicals also have been discussed. The cheminformatics analysis of > 500 natural products extracted from African flora have been reviewed [27, 28].

In another study, 99 species in 81 genera and 45 families from Kenya were summarized and investigated for 278 plant compounds including alkaloids, flavonoids, terpenoids, phenolics, coumarines, polyacetylenes, xanthones, quinones, steroids, and lignans from 2001 to 2013. Twenty-five out of these 278 antimalarial compounds belong to marine plants. All these compounds are organized according to their plant family of origin. After screening of 278 antimalarial compounds, the activities of 171 compounds belonging to the alkaloid and terpenoid classes have been reviewed in the first and second sections, respectively. In vitro and in vivo assays of some derived phytochemicals also have been discussed. The cheminformatics analysis of > 500 natural products extracted from African flora have been reviewed [27, 28].

The activities of 171 compounds belonging to the alkaloid and terpenoid classes have been reviewed in the first and second sections, respectively. In vitro and in vivo assays of some derived phytochemicals also have been discussed. The cheminformatics analysis of > 500 natural products extracted from African flora have been reviewed [27, 28].

In another study, 99 species in 81 genera and 45 families from Kenya were summarized and investigated for in vitro antimalarial activity [29]. The review concludes that about 24.2% species presented antiplasmodial efficacy of IC50 ≤ 5 µg/ml and MeOH root bark extract of *Maytenus obtusifolia* (IC50 < 1.9 µg/ml) was considered to have potential for isolation of antimalarial compounds.

A comprehensive literature search retrieved 286 antimalarial plant species distributed among 75 families and 192 genera in Kenya [30]. The most frequently used plant families were *Asteraceae*, *Fabaceae*, *Lamiaceae*, *Euphorbiaceae*, *Nauclea obtusifolia* ((IC50 < 1.9 µg/ml) was considered to have potential for isolation of antimalarial compounds.

Memvanga and his colleagues evaluated [26] the antimalarial compound in 100 species from Congolese antimalarial plants during the period of 1999–2001, based on in vitro and in vivo analyses. The antimalarial plant data of bio-guided fractionation, isolation, and structure elucidation have been summarized in this review. In vitro antimalarial activity and cytotoxicity of plant-derived components have been reported. The review highlights clinical studies to evaluate safety and the efficacy of quantified extract and commercialized plant-derived products extract. A phase I, IIA, and IIB clinical trial of crude extract from *Nauclea pobequinii* indicated promising results in terms of safety and efficacy as well as fewer side effects. However, these clinical studies did not cover nonimmune patients (e.g., children) which are noticeably more suffered by the malaria disease. This review also presents performed clinical trials of *A., annua* extract on the treatment of malaria in Congo and demonstrates the efficacy of *A., annua* extract to remove malaria symptoms. To potentiate long-term protection of *A. annua* and decrease high rate of recrudescence, combination with *Curcuma longa* extracts was proposed. This review presents two commercialized antimalarial products Manalaria® (Gotu Kola) and Nsansiphos® (*Cephalanthus occidentalis* and *N., latifolia*) that received regulatory approval in Congo.

From 1994 to 2013, 278 plant compounds including alkaloids, flavonoids, terpenoids, phenolics, coumarines, polyacetylenes, xanthones, quinones, steroids, and lignans extracted from African flora have been reviewed [27, 28].

The most potent antiplasmodial natural products have been categorized in detail. Majority of the reviewed compounds were based on in vitro assays; however, fewer were analyzed for cytotoxicity. Also, the less active compounds have been evaluated based on in vivo analysis.
Drug is the most complicated part in development of new antimalarial drug from medicinal plants. Safety of natural products in terms of contradictions, side effects, toxicity, and treatment time are critical issues, which should be carefully considered [35]. The medicinal plant’s safety is of paramount importance for registration/authorization purposes. The potential candidate should pass at least in vitro and in vivo genotoxicity analyses, carcinogenicity, reproductive and developmental toxicity assays, and studies of the effects on drug-metabolizing enzymes [36].

To determine plants potential with high antiplasmodial activity, pharmacological investigations emphasized crude extracts and fractions. Based on published guidelines from WHO and basic criteria for antiplasmodial drug discovery [37, 38], plant extracts can be categorized into three levels based on their antiplasmodial activity as follows: high or pronounced activity (IC50 ≤ 5 μg/ml), good or promising activity (5 μg/ml < IC50 ≤ 15 μg/ml), moderate activity (15 μg/ml < IC50 ≤ 50 μg/ml), and weak activity (50 mg/ml < IC50 < 100 μg/ml). A pure substance is determined as highly active when its IC50 ≤ 1 μg/ml. Also, extracts that exhibit 50% of Plasmodium schizonts maturation at concentrations < 5 mg/ml were considered significant antimalarial leads [26]. Next, the cytotoxicity of plant-derived compounds on human cells should also be considered for the antiplasmodial activity. To evaluate the plant extract or isolated compounds for their efficacy against the Plasmodium parasite compared to its cytotoxicity for mammalian cells, their selectivity index (SI) has been defined. The cytotoxic CC50 value ratio on a cell line to the antiparasitic IC50 value on a P. falciparum strain is calculated as SI. According to Camacho analysis [39] the extracts or fractions are selective against the Plasmodium parasite if IS value is greater than 1.0. In contrast, extracts or fractions with SI lower than 1.0 are selective against the cell line used. Therefore, plant-derived antimalarial compounds with SI greater than 1.0 can be considered for further investigations. However, SI values for lead compounds must be greater than 10–100 [37, 38].

In the classic discovery for natural products, the compounds are commonly investigated in vivo only after in vitro characterization. Nevertheless, screening of drug (compound isolation, structure elucidation, structure–activity relationship, lead optimization, clinical trials, and authorization for product launch) by this method is prolonged, inefficient, and expensive. The journey of product development is time consuming (10–15 years) from the concept to clinical trials and also requires a whopping investment of US $ 1 to 1.5 billion [40]. Additionally, product development cost ends up with a high price that often results in its unavailability and unaffordability in developing countries. Furthermore, the pharmaceutical industries are searching beyond classical drug discovery and development concepts that accelerate the process and

**Novel Antimalarial Natural Products Discovery**

The discovery and isolation of novel therapeutic candidates in numerous medicinal plant resources are foundation of developing antimalarial drugs or phytomedicines. In this case, basic methodologies have been applied in the selection of medicinal plants for further analysis in drug discovery and development. They included mass screening of plants, ethnomedicinal uses, available databases, and chemotaxonomic approaches [33, 34]. The selection of the ideal leads with the high efficacy and safety properties as antimalarial drug is the most complicated part in development of new antimalarial activities (n = 135, 97.1%; IC50 μg/ml), bioactive compound, and toxicity.

Combined survey of traditional healers and literature search about herbal medicines traditionally used for malaria treatment in Democratic Republic of Congo (DRC) region were reviewed in [31]. Direct interview of 32 traditional healers characterized 45 plant species among 21 botanical families and 41 genera. Artemisia annua L., (Asteraceae) and Carica papaya L., (Caricaceae) were the most frequently claimed. The diverse remedy preparation methods include decoction, infusion, maceration, sap extraction, juice extraction, powder, ash, and ovule. Combinatory use of these remedies generated 25 multi-herbal and 27 monoherbal recipes by traditional healers. The study also retrieved 194 plant species belonging to 69 families and 164 genera that were previously documented for malaria treatment in DRC region and compared them with those identified by traditional healers. Only 38% of surveyed medicinal plant species were cited previously by other studies.

The review by [32] was obtained from African Compound Libraries from 2013 to 2019, which is constantly updated. The bulk of 187 natural compounds from plants which demonstrated variety of antimalarial/antiplasmodial activity mainly consisted of terpenoids, flavonoids, alkaloids, and quinones with percentage more than 5% in the entire compound collection. Also, most antimalarial/antiplasmodial compounds were derived from plant species family Rubiaceae. The most active compounds belonged to the same classes from which the natural origins of current antimalaria drugs are derived, such as quinine from alkaloid and artemisinin from terpenoid.
guarantee that efficient and safe drugs could be released faster and sustained reverse pharmacology, also known as bedside to bench, is a multidisciplinary procedure empha-
sing on conventional knowledge, experimental observation, and clinical experience [43]. Reverse pharmacology is associated with reversing the routine ‘laboratory to clinical discovery’ to ‘clinical to laboratory practice’ [41]. This approach can add balance to current approaches, such as when first-line treatment is not available and can be employed to decline the progress of resistance to existing standard drugs. Reverse pharmacology has been successful-
ly used to develop antimalarial phyto medicine derived from *Argemone mexicana* decoction [42]. *Argemone mexicana* has been investigated for reverse pharmacology process in Mali and categorized into 4 stages, including selection of the remedy, dose-escalating clinical trials, randomized control, and isolation of tested compounds [42]. This example of reverse pharmacology demonstrates that a standardized phytomedicine development is faster and cost effective in comparison to conventional drugs and that can be an efficient alternative approach for the development of a validated phytomedicine [43]. Several antimalaria phyto medicines have been successfully developed and have received government authorization in Ghana (*Cryptolepis sanguinolenta* root infusion), in Burkina Faso (*Cochlospernum planchonii* root decoction) [22], and the Democratic Republic of Congo (*A. annua* Anamed leaf infusion) [44]. The examples are reported as safe and effective in pre-clinical trials; however, further investigations are required to investigate their effectiveness in public health strategies to manage and eradicate malaria. Moreover, inexpensive and reliable tests are needed to perform quality control and optimization of plant materials. Besides efficacy, the drug dosage is equally important for standardizing medicinal plant formulations. In the context of standardization, there are several key factors to consider, such as drug quality, physical, chemical, phytochemical, and standardization, as well as in vitro and in vivo parameters which are equally important. Optimization is complex because plant’s genetic and environmental factors are critical contributors for variability in herbal preparation. Also, the raw material is supplied in batches that can vary in active compounds. Therefore uniform optimization regarding quality among different batches are hard to control and ascertain [45]. Furthermore, the absence of regulatory standards regarding herbal medicine preparation and clinical evaluation makes product development complicated and difficult.

**Whole Plant or Its Isolated Natural Products Against Malaria**

A major complexity in discovering single-active constitu-
ent as new drug from plants stems is the efficacy of most plant natural products associated synergistically with diverse components rather than a single compound [46, 47]. This complexity hinders the development for discovery of novel natural product for antimalarial agents. Natural medicines’ synergistic actions come from evolutionary responses toward invaders [48]. As a self-defense mechanism, plants synthesized and secreted antimicrobials to fight against pathogens and, in the response, pathogens developed their resistant systems for survival. In the next step, plants were induced to develop resistant inhibitors [49]. A crude extract can then contain both resistant inhibitors and their potentiators [50]. Synergistic interactions are the body of the pharmacody-
namic augmentation, where different constituents in the crude extract provide a combined effect. In this context, the *in-vitro* antiplasmodial activity of 14 medicinal plants indicated that berberine was the single most active antimalarial compound [51]. However, extracted flavonoids from the same plant have been demonstrated to remove resistance toward berberine in microbes. Thus, while berberine may be the most important antimicrobial, eliminating flavonoids could lead to the development of microbial resistance to berberine and may account for its failure as an antimicrobial [52].

The principal synergistic combination of antimalaria-
s were addressed with Malarone® (atovaquone–proguanil) [53] and Quinimax® (quinine–quinidine–cinchonine) [54, 55]. The product Malarone® as an antimalarial is demonstrat-
ed for prophylaxis of *P. falciparum*, including in areas where chloroquine resistance has been reported. Synergistic combination has been documented not only for reversal resistance but also for other positive interaction, including complementary mechanisms of action (improving bioavailability or decreasing metabolism and excretion and immunomodulation) and modulation of side effects. The synergistic combination can occur among different plants or phytochemical and a synthetic drug. Table 1 summarizes example of synergistic combination of natural plant products in treatment of malaria.

The positive effects of synergistic combination indicated that crude plant extracts or a mixture of plants that could generally have greater in vitro/in vivo antiplasmodial activity than a single compound at an equivalent dose [56]. Moreo-
ver, it has also been demonstrated that the combination strategy can decrease the toxicity of single-active compounds to the microorganism. In this case, Quinimax is an example of standardized mixture of cinchona alkaloids that exhibits less cinchonism and prolongation of the QTc interval than
### Table 1: A summarized synergistic combination of plant natural products in the treatment of malaria

| Positive interaction | Combination | Mechanism of action | FIC | Reference |
|----------------------|-------------|---------------------|-----|-----------|
| Chloroquine resistant malaria | *Cinchona* alkaloids (quinine with quinidine and cinchonine) | Not defined | Lower than 1 | [118] |
| Artemetin and flavones casticin | Casticin enhances the in vitro activity of artemisinin by 3–fivefold by high antioxidant/radical scavenging activities | Not defined | [119] |
| Picroliv (*Picrohiza kurroa*)-chloroquine | Picroliv enhancing chloroquine efficacy against experimental murine malaria by induction of strong immuno-potentiating response | Not defined | [120] |
| *Andrographis paniculata* and *Hedyotis corymbosa* extracts – Curcumin | The extracted plant material inhibits the ring stage of the parasite and increases the Curcumin efficacy | Lower than 1 | [121] |
| Chloroquine-*Vernonia amygdalina* leaf extract | Restore the prophylactic and therapeutic efficacy of chloroquine against *Plasmodium berghei* malaria in mice | Not defined | [122] |
| Chloroquine- *Bidens pilosa* leaves | *B. pilosa* extract reverses resistance to chloroquine | Not defined | [123] |
| Crude alkaloids of *Strychnos myrtoides* Gilg & Busse-chloroquine | The extract enhances chloroquine effectiveness against a chloroquine-resistant strain of *Plasmodium falciparum* | Not defined | [124] |
| Icajine, isoretuline, and strychnobrasiline (*Strychnos plants*) – mefloquine and icajine—chloroquine | Reverse chloroquine resistance in in vitro tests with *P. falciparum* | Not defined | [125] |
| EGCG (green tea)-artemisinin | EGCG potentiates the antimalarial effects of artemisinin without interfering with the folate pathway | Not defined | [126] |
| Complementary mechanisms of action | Curcumin–Artemisinin | Curcumin inhibits both CYP2B6 and CYP3A4 involved in the human liver metabolism of artemisinin | Lower than 1 | [127] |
| *Artesunate* - *Telfairia occidentalis* | *T. occidentalis* enhanced hematological parameters and rapid rate of recovery in *P. berghei*-infected mice | Not defined | [128] |
| Curcumin- piperine (*Piper nigrum seeds*) | Piperine boosts the bioavailability of curcumin by 2000% in humans by inhibition of glucuronidation and reduction of the gastrointestinal transit and also increased its serum concentration, and absorption | Not defined | [129] |
| (-)-Epigallocatechin-3-gallate (EGCG) (green tea) and piperine(black pepper) | Piperine enhanced the bioavailability ECGG by inhibiting glucuronidation and gastrointestinal transit | Not defined | [130] |
| Curcumin (*Curcuma longa L*-arteether | Curcumin increases the efficacy of arteether against *P. berghei*-infected mice by activation of TLR2-mediated innate immune response which induce production of anti-parasite antibodies | lower than 1 | [131] |
| Decrease adverse effects | Glycyrhiza glabra, *Ziziphus jujube* and *Zingiber officinale* Febrifugine | The extracted plant material may be attenuated any hepatotoxicity from febrifugine | Not defined | [132] |
Modern drugs are inaccessible and unaffordable. The efficacy of herbal remedies for use in poor regions where the activity of existing pharmaceutical preparations and the derived compounds and/or medicinal plant extracts to boost codynamic synergy and safety of combination of plant-derived compounds and/or medicinal plant extracts to boost the activity of existing pharmaceutical preparations and the efficacy of herbal remedies for use in poor regions where modern drugs are inaccessible and unaffordable.

Production of Malaria Therapeutics in Plants

Lower concentration of active molecules in source plants is one of the major concerns related to natural producers. The location and environmental condition which account for slower growth may negatively affect the production and recovery of natural products. Subsequently, larger quantities of biomass are required to fulfill the demands of commercial production of active molecules [60, 61]. Considering that active drugs should be produced inexpensively in much more significant quantities than currently available ones, genetic engineering plays a pivotal role to expand available metabolic repertoire or to express the entire biosynthesis pathways into host plants with proper functionality [62, 63]. Artemisinin is an antimalarial compound and is naturally produced in A. annua in low level [64, 65], which led to relatively high costs for isolation and purification. Although, in the last decade the amount of artemisinin has been increased by 36-fold [66], an efficient prophylactic approach could be in great demand in the endemic countries. The worldwide demand each year for artemisinin is around 119 metric tons (MT), while the amount of A. annua in its aerial parts is 0.01–1.2% which is not enough to meet growing demands [67]. Moreover, chemical synthesis of artemisinin makes the price unaffordable to most patients in remote areas.

Different approaches by metabolic engineering have been applied to enhance artemisinin production by overexpressing genes involved in the biosynthetic pathway of artemisinin. [68]. Artemisinin synthesis can be considerably improved by overexpressing HMGR and ADS in A. annua [69] and also, artemisinin production has been increased by expressing HMGR and FPS together in A. annua [70]. Overexpression of FPS in A. annua leads to the accumulation of the increased amount of artemisinin through conversion of IPP and DMADP into FDP. Recent attempts have been made to induce the expression of a novel biosynthetic pathway of artemisinin in transgenic tobacco plants [71–75]. The best strategy to obtain high content of artemisinin in transgenic plant was established via the expression of artemisinin pathway genes in chloroplast [73]. The transgenic plants showed a threefold enhancement of isopentenyl pyrophosphate, and targeting AACPR, DBR2, and CYP71AV1 to chloroplasts resulted in higher expression and an efficient photo-oxidation of dihydroartemisinic acid to artemisinin. This strategy successfully enhanced artemisinin production with capacity of 0.8 mg/g (DW) tobacco leaves [73], which is the highest level of artemisinin produced in transgenic plant reported to date.

Besides tobacco plants, mosses Physcomitrella patens has been utilized as a production host for artemisinin. Recently, integrating the biosynthetic pathway of artemisinin by incorporating five-related genes into the moss genome was successfully performed. These genes were ADS, amorphadiene synthase; CYP71AV1, amorphadiene oxidase; ADH1, alcohol dehydrogenase-1; DBR2, artemisinic aldehyde double-bond reductase; ALDH1, aldehyde dehydrogenase-1 that resulted in a high initial production of 0.21 mg/g dry weight artemisinin after 3 days of cultivation [76].

Plant cell cultures are utilized as alternative production system for antimalarial-active molecules [77–80] at a scale of ~1000 L or higher [81]. Although, the production cost is relatively higher because of the requirement for fermentation equipment, growth media as well as sterile handling during upstream process, but cell cultures are preferred as suspension obtained from native or relative species. This is advantageous because intrinsic metabolic capability can be boosted by genetic engineering, hairy root cultures, precursor feeding, elicitation, permeabilization, and growth regulators to increase yields [82–86]. Such strategy was implemented by different research groups to enhance the yield of artemisinin [77, 87–89] (Fig. 1).

Plant-based antimalarial products’ success is significantly contingent to bulk production system, which provide large production of high-quality drugs for formulation and
| Vaccine targeting | Antigen | Antigen description | Plant/ expression system | Vaccine mechanism | Expression level | Vaccine immuno-genicity | Reference |
|------------------|---------|---------------------|--------------------------|------------------|-----------------|------------------------|-----------|
| Blood stages     | MSP1\(_{19}\) | *P. falciparum* malaria surface protein 1 | Tobacco/nuclear transformation | Targets merozoite surface to inhibit erythrocyte invasion | 0.0035% TSP | Not reported | [129] |
| MSP4/5           | *P. yoelii* malaria surface protein 4/5 | Tobacco/nuclear transformation; Tobacco/ transient expression (magnICON viral vector) | Targets merozoite surface to inhibit erythrocyte invasion | 0.02–0.04% TSP; 10%; TSP(1–2 mg/g FW) | Induced antigen-specific antibodies in mice via parenteral and orally (following DNA vaccination) delivery; induced specific antibodies by oral delivery or primed by DNA vaccine to mice | [133, 134] |
| MSP1\(_{19}\)   | *P. yoelii* malaria surface protein 1 | Tobacco/transient expression (magnICON viral vector) | Targets merozoite surface to inhibit erythrocyte invasion | 23% TSP (3–4 mg/g FW) | MSP1\(_{19}\) produced in tobacco leaves was immunogenic by intraperitoneal delivery with Freund’s adjuvant or oral administration without adjuvant | [135] |
| MSP1\(_{42}\)   | *P. yoelii* malaria surface protein 1 | Arabidopsis seeds / stable transformation by targeting the protein-to-protein storage vacuoles or fusing with stable plant storage protein | Targets merozoite surface to inhibit erythrocyte invasion | 5% TSP | Showed immunogenicity against sera from malaria-infected patients | [136] |
| MSP1 (CTB fusion protein) | *P. falciparum* malaria surface protein 1 | Lettuce/chloroplast transformation; tobacco/chloroplast transformation | Targets merozoite surface to inhibit erythrocyte invasion | Up to 6.1% TSP; 10.11% TSP | Immunoreactivity to native parasite proteins; oral administration of CTB-PfMSP1 exhibited immune response in animal model, priming T-cell responses and inducing PfMSP1-specific antibodies | [137] |
| Vaccine targeting | Antigen | Antigen description | Plant/ expression system | Vaccine mechanism | Expression level | Vaccine immunogenicity | Reference |
|-------------------|---------|---------------------|--------------------------|------------------|------------------|----------------------|-----------|
| AMA1 (CTB fusion protein) | *P. falciparum* apical membrane antigen 1 | Lettuce/chloroplast transformation; tobacco/chloroplast transformation | Targets the merozoite's invasion apparatus to prevent erythrocyte infection | 7.3% TSP; 13.1% TSP | Immunoreactivity to native parasite proteins oral administration of CTB-PfMSP1 fusion protein was immunogenic in mice, priming T-cell responses and inducing PfMSP1-specific antibodies | [137] |
| MSP1 | *P. vivax* merozoite surface protein 1 | *Brassica napus*/nuclear transformation | Targets merozoite surface to inhibit erythrocyte invasion | Not defined | Oral immunization of mice with plant-derived recombinant elicited antigen-specific IgG1 production and the Th1-related cytokines IL-12 (p40), TNF, and IFN-γ increased in the spleens of the BALB/c mice | [138] |
| CSP | *P. vivax* circumsporozoite protein | *Brassica napus*/nuclear transformation | Inhibits sporozoite motility, prevents hepatocyte invasion | Not defined | Orally gavaged mice with plant-made PDs incited the antigen-specific IgG1 production and the Th1-related cytokines IL-12 (p40), TNF, and IFN-γ increased in the spleens of the BALB/c mice | [138] |
| PfS230 | *P. falciparum* surface protein 230 | Tobacco/transient expression (agroinfiltration) | Inhibits ookinete development in the mosquito midgut (sexual stage) | 800 mg/kg FW | Induction of immune responses in rabbits' model with high titer of transmission-blocking antibodies and reduction in oocysts counts by 99% | [139] |
| Vaccine targeting | Antigen | Antigen description | Plant/ expression system | Vaccine mechanism | Expression level | Vaccine immunogenicity | Reference |
|------------------|---------|---------------------|--------------------------|-------------------|-----------------|------------------------|-----------|
| Pfs25-FhCMB      | P. falciparum surface protein 25 fused to LicKM carrier | N. benthamiana transient expression (agroinfiltration) | Inhibits ookinete development in the mosquito midgut (sexual stage) | 0.14 mg/g FW | Non-glycosylated, fusion Pfs25-FhCMB elicited immunogenicity and resulted in strong transmission-blocking activity in mice and rabbit up to 6 month | [140] |
| Pfs25-CP VLP)    | P. falciparum surface protein 25 | N. benthamiana transient expression (Tobacco mosaic virus-based launch vector) | Inhibits ookinete development in the mosquito midgut (sexual stage) | 0.05 mg/g FW | Induction of functional immune responses using a two dose or a single-dose vaccination of Pfs25-CP VLP, Induction of transmission-blocking antibodies | [146] |
| Pfs2522-193      | P. falciparum surface protein 25 | Green alga Ch. reinhardtii/chloroplast transformation | Inhibits ookinete development in the mosquito midgut (sexual stage) | 0.5% TSP; 0.2% TSP | Algae-produced Pfs25 elicited transmission-blocking antibodies by standard membrane feed assay; algae-produced Pfs28 elicited transmission-blocking antibodies by standard membrane feed assay | [141] |
| Pfs28            | P. falciparum surface protein 25 fused to the β-subunit of the cholera toxin | Green alga Ch. reinhardtii/chloroplast transformation | Inhibits ookinete development in the mosquito midgut (sexual stage) | 0.09% TSP | Oral vaccination elicited CtxB-specific serum IgG antibodies and both CtxB- and Pfs25-specific secretory IgA antibodies. CTB-Pfs25, no immune response and no transmission-blocking activity | [147] |
| Vaccine targeting       | Antigen     | Antigen description                                                                 | Plant/ expression system       | Vaccine mechanism                                                                 | Expression level   | Vaccine immunogenicity                                                                 | Reference |
|-------------------------|-------------|--------------------------------------------------------------------------------------|--------------------------------|----------------------------------------------------------------------------------|-------------------|----------------------------------------------------------------------------------------|-----------|
|                         | F0          | *P. falciparum* surface protein 25 and the C0-domain of *Pfs230*                     | *N. benthamiana* transient expression | Inhibits ookinete development in the mosquito midgut (sexual stage)               | 300 mg/g FLW      | Plant-derived PDs halted the formation of oocysts in a malaria transmission-blocking assay | [142]     |
|                         | GAP50       | *P. falciparum* gliding-associated protein 50                                        | *N. benthamiana* transient expression platform using endoplasmic reticulum (ER) and plastid targeting | Inhibit the actin–myosin motor complex-driven invasion machinery (glideosome). Inhibit the protection of the gametes from complement-mediated lysis | ER- GAP50: 4.1 μg/g FW Plastid GAP50: 16.2 μg/g | Induced antigen-specific antibodies in rabbit and PIGAP50-specific rabbit immune IgG inhibit zygote development by up to 55% | [143]     |
| Pre-erythrocytic stage  | CCT         | Three fusion proteins PfCelTOS, PfCSP, and PfTRAP                                     | *N. benthamiana* transient expression (agroinfiltration) | Inhibits sporozoite motility, prevents hepatocyte invasion                         | up to 2 mg/g FW   | The study was successful to provoke immune responses against the pre-erythrocytic stage of *P. falciparum* | [144]     |
| Multi-stage vaccine     | CCT:E3:F0:gAMA1 | (CCT: pre-erythrocytic stage: *PfCSP* _TSR, PfCelTos and PfTRAP_TSR; E3: bloodstage:*PfMSP1-19_EGF1, PfMSP4_EGF, PfMSP8_EGF1, PfMSP8_EGF2 and PfMSP3; F0: sexual stage: *Pfs25 and *Pfs230) | *N. benthamiana* transient expression (agroinfiltration) | Multi-stage, multi-antigen                                                        | 1 mg/g FW for CCT and gAMA1 and up to 250 μg/g FW for E3 and F0 | The domain-specific antibody titers as well as component-specific antibody concentrations were determined in immunized rabbits and strong inhibition in pre-erythrocytic (up to 80%), blood (up to 90%), and sexual parasite stages (100%) was reported | [145]     |
| Antigen description | Plant/ expression system | Vaccine mechanism | Expression level | Vaccine immunogenicity |
|---------------------|-------------------------|------------------|-----------------|----------------------|
| P3: pre-erythrocytic stage: Pf CelTOS, Pf CSP_TSR, and Pf TRAP_TSR; M8: the Multi-Domain, Multi-Stage Vaccine: Pf Msp1-19_EGF1, Pf Msp8_EGF1/2, Pf Msp4_EGF, Pf Ripr_EGF6, Pf CelTOS, Pfs25, Pf 230-C0, Pf CSP_TSR, Pf CeTOS, Pf Pgs25, Pf CSP_TSR, Pf Pgs25, and Pf Msp1-19_EGF1; E5: the Multi-EGF Dual-Stage Vaccine (blood stages and sexual stages): Pf Msp1-19_EGF1, Pf Msp4_EGF, and Pf Msp4_EGF, and Pf Msp1-19_EGF1 | N. benthamiana/ transient expression (agroinfiltration) | Multi-stage, multi-antigen | Up to 100 μg/g FLW for P3 and up to 15 μg of μg/g FLW for E5 and report for M8 | The efficacy of P3 vaccine candidate to inhibit pre-erythrocytic parasites (up to 80%) as well as its immunogenicity in rabbits was reported. Like P3, E5 and M8 indicated robust immunogenicity in mouse |

Reference [145]
characterization. In this context, molecular biopharming is a useful tool to overexpress potential contents of plant-derived antimalarial drugs and facilitate the large-scale production of drugs (Fig. 2). Considering the plant expression system, tobacco and *N. benthamiana* are currently utilized as standard systems for stable and transient foreign proteins production, respectively [90]. Transgenic tobacco plant is an efficient and sustainable platform for producing heterologous proteins because crop can be grown in sterile conditions without antibiotics and large leaves biomass account for large production and can be harvested several times a year. Moreover, each tobacco plant can produce nearly a million seeds per season [91] and high biomass yield of 91,000 tons a⁻¹ km⁻² in the case of using vertical farming units (VFUs), allowing production of pharmaceuticals in multiple tons with low cost enough to fulfill high-demand markets [92]. *N. benthamiana* also is ideal system foreign proteins because of its hefty biomass production ranged from 3500 to 7000 kg per week as reported by the Caliber Biotherapeutics facility 89. Moreover, ease of transformation with well-optimized protocol available, subsequent selection and development of target recombinant protein, ability to process glycosylated proteins, and cost-effective upscale production of 150 kg/year of purified product are substantial technical advantages of plant platforms over mammalian cells or cellular-based systems [93].

### Plant-Derived Vaccine Against Malaria

The vaccine development approach stems from the fact that recurring drug resistance can compromise the efficiency of both old (use of insecticide-treated bed nets and indoor residual spraying) and new antimalarial medicines [17]. Albeit intensive research on vaccine development against malaria, there is still no vaccine available that can provide sustained immunity. The vaccine could be considered a promising alternative tool for controlling and preventing malaria, proven as an efficient and cost-effective tool for control and management of other infectious diseases. To develop an effective malaria vaccine, attempts have been made to understand the parasite life cycle classified into liver, blood, and mosquito stages. All these stages have a great potential for the development of malaria vaccine in order to elicit immune response [94]. Several aspects have been investigated to produce potential malaria vaccine candidate antigens, domains, and epitopes, and several have been advanced into pre-clinical and advanced clinical trials [95]. *Plasmodium falciparum*
circumsporozoite protein (CSP)-based Mosquirix (RTS, S) developed by GSK is the most advanced malaria vaccine that could enter the market [96]. Like all other drugs development, the process of plant-made product development may take several years to secure regulatory approval (Fig. 3), and currently the regulations in Europe and the USA are tight to move forward any plant-made products. However, recently Covid-19 pandemic has made the regulators look for alternative method of production such as plant for scalable and cost-effective methods to mitigate the infections.

Although there is no report on the production of efficient vaccine which provides immunity against malaria, several candidate antigens against different stages of the parasite life cycle have been expressed using transient expression or stably transformed plants [97]. Upon oral delivery for immunization, production of neutralizing antibodies is reported in plant-made vaccine candidates. Those also enhanced immunogenicity with long-lasting TBA resulted in protective immune response in animal model [96, 97]. Subcellular targeting of malaria recombinant vaccine in reticulum endoplasmic (RE) showed that N-glycosylation was limited.
to high-mannose glycoforms [98], which do not contain potentially allergenic plant-specific glycan modifications [98, 99]. This concept has been recently used for high-level production of PfAMA1 (> 510 µg/g fresh leaf weight) in RE of N. benthamiana plants and it was indicated that nonglycosylated antigen could adopt a native conformation and elicit strong growth inhibitory antibody responses in rabbits [100].

**Transient Expression Systems as Malaria Therapies**

Transient expression systems for recombinant protein production are favored because it allows large-scale production in weeks in cost-effective manner without genomic alterations. Compared to conventional cell culture-based and transgenic plants-based approaches that require long-developmental cycles, transient expression systems are promising alternatives for producing antimalarial vaccine in a relatively shorter time. The transient expression can be obtained systematically by infection of plant with replicating virus containing the sequence of a desired recombinant protein [101]. The transient expression can also be obtained by infiltration of tobacco or by its closely related N. benthamiana with Agrobacterium tumefaciens carrying vector with desired gene sequence. In this context, desired gene can be transferred to the plant via T-DNA plasmid, which is part of a binary vector system in agrobacterium. Provided that expression vector remains an episomal DNA molecule, the gene expression is not altered by position effects. Moreover, due to genome integration-independent strategy, those of concerns related to spread of transgenic plants could be avoided. Additionally, by this system the expression of transgene can be determined within 3 h after transformation and after 18–48 h reaches the expression plateau and remains transcriptionally active for ~10 days [84, 101].

In the early phase of molecular farming, systemic and agro-infection were considered separate and competing strategies to produce recombinant proteins. However, during last decades, evidence indicated that agro-infection is more effective method for replicating viruses containing gene of interest. The latest landmark advancement in molecular farming and the emergence of deconstructed vectors rely on available plant viruses [102, 103]. In this new generation of vectors, unwanted viral genome components have been eliminated, leading to the assembly larger transgene while maintaining viral replication and transcription. Moreover, agroinoculation can remove limitations related to mechanically inoculation of nucleic acid into plants by virus vector and deliver targeted genes into plant cells [103]. MagnICON system as a deconstructed viral vector has been demonstrated for rapid, high-level accumulation of numerous pharmaceuticals, up to 1 mg/g (FW) in shorter duration (7–10 days after agroinfiltration) [104–107], some of which are recently undergoing clinical evaluation [103]. The utilization of this system also has been reported for high production of malaria asexual blood-stage subunit vaccine, PyMSP4/5 (1–2 mg/g Fwt) and MSP119 (3–4 mg/g Fwt) in N. benthamiana, and immunogenicity of both plant-made proteins was approved [108]. However, one of the challenges in transient expression system is the yield deviation among batches [109], which points out the process reproducibility concerns [110]. To ensure consistency, improvement of process parameter controls such as incubation time and temperature using VFUs facility could overcome such challenge [111]. Comprehensive information related to VFUs has been reviewed by Fischer and colleagues [110]. This approach has been successfully implemented for transient expression of recombinant proteins involved in influenza pandemic [112] and received governmental endorsement in the USA (Paul, et al. 2013). Spiegel and colleagues investigated the scalable transient expression platform for vaccine development against malaria [113]. Large quantity of targets comprising various stages of Plasmodium falciparum life cycle were investigated as potential vaccine candidates. In their research the results have demonstrated that transient expression is essential for developing multi-domain vaccine candidates against malaria that also offers scalability with convenience.

**Leafy Plants as Promising Strategy for Oral Delivery of Malaria Vaccines**

The global malaria vaccines market has grown significantly in the last few years, with market value of US$ 8.5 million in 2018. The market value is expected to reach approx. at a CAGR of 102.8% by 2024 as published by Coherent Market Insights. The growing demand for vaccine provokes the scientific community to discover alternative methods for its production at larger scale to meet future demands, worldwide. Malaria Vaccine Decision-Making framework estimated the cost of US$7 per dose, plus a $5 delivery cost for a vaccine targeting *P. falciparum*. However, drug availability at these huge costs make it unaffordable to most of the global population, as one-third earns less than $2 per day [114]. The large-scale production of PDs and its delivery are major factors that contribute to vaccine cost. These limits should be addressed by developing new strategies to reduce costs related to production and delivery of vaccine. An affordable malaria vaccine should be cost effective, efficient, and heat stable, requiring no skilled medical worker for its administration. Using genetic engineering in edible leafy plants for production of malaria vaccine and further oral administration of produced proteins can significantly overcome those hurdles related to downstream process.
In the past decades, significant efforts have been made to produce therapeutics proteins in transplastomic plants and the first report on production of recombinant protein and vaccine in transplastomic tobacco [114] opened new window in molecular farming. Compared to nuclear transformation system, integration of foreign gene into chloroplast genome occurs by homologous recombination, eliminating gene silencing and positional effects as well as pleiotropic effects involved in gene expression variation. Owing to the polyploidy of the chloroplast system with the presence of thousands of genomes per cell, astounding high level of protein production up to 72% of the total soluble protein was achieved [114]. Moreover, the incidence of horizontal gene transfer could be minimized due to maternal inheritance of chloroplast genome, offering transgene containment compared to pollination. Orally delivered CTB-fused malaria proteins, AMA1 and MSP1 bioencapsulated in tobacco chloroplast elicited antibodies in mice and completely inhibited proliferation of the malarial parasite and cross-reacted with the native parasite proteins [115]. This strategy has also been used for production of CTB-Pfs25 of *Ch. reinhardtii* the native parasite proteins [115]. This strategy has also been used for production of CTB-Pfs25 of *Ch. reinhardtii* and oral delivery of freeze-dried whole cells elicited CTB-specific IgG antibodies and secretory IgA antibodies to both CTB and Pfs25 [116, 117].

**Conclusion**

The incidence of malaria infection is likely to increase because of socioeconomic conditions along with climate change and migration, the lack of coherent policy by health authorities for curbing the disease spread, and resistance to antimalarial drugs particularly single-drug administration in developing countries. The escalating population in the developing world with mushrooming malaria infections will increase demand for antimalaria agents. Regardless of advancement in biotechnological processes to provide enough supply for such agents, the production system of those are based on microbes or mammalian cells cultures limited in capacity which are unlikely to meet hiking future market demands. Therefore, as promising alternative, plants have natural ability to produce agents with antimalaria function such as quinine, lapinone, and artemisinin as well as the capacity to meet the challenge of producing effective and affordable protein drugs. The recent regulatory approval of orally delivered Palforzia by FDA will encourage the scientific community to bring more of their product to clinical trials following same regulatory pathway. In addition, advancement in stable, transient-based technologies is required to manufacture malaria related compounds those are capable to reduce price tag, eliminate the cold chain requirement, avoid downstream processing by oral delivery, increase the bioavailability by passing degradation. Also, scalability of these transient production system is critical and require further research to meet future needs and save millions of lives worldwide.

**Funding** Not applicable.

**Data Availability** Not applicable.

**Code Availability** Not applicable.

**Declarations**

**Conflicts of Interest** No conflict of interest.

**Ethical Approval** Not applicable.

**Consent to Participate** Not applicable.

**Consent for Publication** Not applicable.

**References**

1. Lopez, G. R., Hernan, C., Moreno, L., Fernandez, E. V., Munoz, M. F., Delgado, A., Polo, M. J., & Andres, I. (2014). Malaria in developing countries. *Journal of Infection in Developing Countries*, 8, 1–4.
2. Gamo, F.-J., Sanz, L. M., Vidal, J., de Cozar, C., Alvarez, E., Lavandera, J.-L., Vanderwall, D. E., Green, D. V., Kumar, V., & Hasan, S. (2010). Thousands of chemical starting points for antimalarial lead identification. *Nature*, 465, 305.
3. Qayum, A., Arya, R., & Lynn, A. M. (2016). Ethnobotanical perspective of antimalarial plants: Traditional knowledge-based study. *BMC Research Notes*, 9, 67.
4. WHO (2019) World malaria report: World Health Organization. licence (CC BY-NC-SA 3.0 IGO: https://creativecommons.org/licenses/by-nc-sa/3.0/igo/).
5. Amimo, F., Lambert, B., & Magit, A. (2020). What does the COVID-19 pandemic mean for HIV, tuberculosis, and malaria control? *Tropical Medical Health*, 48, 32–32.
6. Sherrard-Smith, E., Hogan, A. B., Hamlet, A., Watson, O. J., Whittaker, C., Winskill, P., Ali, F., Mohammad, A. B., Uhomobhi, P., Maikore, I., Ogobafor, N., Nikau, J., Kont, M. D., Challengier, J. D., Verity, R., Lambert, B., Cairns, M., Rao, B., Baguelin, M., … Churcher, T. S. (2020). The potential public health consequences of COVID-19 on malaria in Africa. *Nature Medicine*, 26, 1411–1416.
7. WHO (2020) Global Malaria Programme: Tailoring Malaria Interventions in the COVID-19 Response. Retrieved from https://www.who.int/publications/m/item/tailoring-malaria-interventions-in-the-covid-19-response
8. Hoffman, S. L., Vekemans, J., Richie, T. L., & Duffy, P. E. (2015). The march toward malaria vaccines. *Vaccine*, 33, D13–D23.
9. Cox, F. E. (2010). History of the discovery of the malaria parasites and their vectors. *Parasites & Vectors*, 3(5), 2014.
10. Gaillard, T., Madamet, M., Tsombeng, F. F., Dormoi, J., & Pradines, B. (2016). Antibiotics in malaria therapy: Which antibiotics except tetracyclines and macrolides may be used against malaria? *Malaria Journal*, 15, 556–556.

© Springer
11. Mishra, M., Mishra, V. K., Kashaw, V., Iyer, A. K., & Kashaw, S. K. (2017). Comprehensive review on various strategies for antimalarial drug discovery. European Journal of Medicinal Chemistry, 125, 1300–1320.
12. Gorobets, N. Y., Sedash, Y. V., Singh, B. K., & Rathi, B. (2017). An overview of currently available antimalarials. Current Topics in Medicinal Chemistry, 17, 2143–2157.
13. WHO (2013). Stuffy, World malaria report.
14. Haldar, K., Bhattacharjee, S., & Safeukui, I. (2018). Drug resistance in Plasmodium. Nature Reviews Microbiology, 16, 156.
15. Nsanzabana, C., Djalle, D., Guérin, P. J., Ménard, D., & González, I. J. (2018). Tools for surveillance of anti-malarial drug resistance: An assessment of the current landscape. Malaria Journal, 17, 75.
16. WHO (2010). Global report on antimalarial drug efficacy and drug resistance, 2000–2010.
17. Organization, WH. (2015). Guidelines for the treatment of malaria, World Health Organization.
18. Ashley, E. A., & Phyo, A. P. (2018). Drugs in development for malaria. Drugs, 78, 861–879.
19. Okombo, J., & Chibale, K. (2018). Recent updates in the discovery and development of novel antimalarial drug candidates. Medical Chemistry Communication, 9, 437–453.
20. Ramakrishnan, G., Chandra, N., & Srinivasan, N. (2017). Exploring anti-malarial potential of FDA approved drugs: An in silico approach. Malaria Journal, 16, 290–290.
21. Travassos, M., Laufer, M (2017). Antimalarial drugs: An overview. UpToDate Waltham MA: Topic 468 Version 28.0
22. Willcox, M. L., & Bodeker, G. (2017). Plant derived antimalarial agents. Medical Chemistry Communication, 9, 437–453.
23. Suleman, S., Beyene, T. T., Kebebe, D., Belew, S., Mekonnen, Y., Gashe, F., Mussa, S., Wynendaele, E., Duchateau, L., & De Spiegeleer, B. (2018). Treatment of malaria and related symptoms using traditional herbal medicine in Ethiopia. Journal Ethnopharmacology, 213, 262–279.
24. Kaur, R., & Kaur, H. (2017). Plant derived antimalarial agents. Journal of Medicinal Plants, 5, 346–363.
25. Nogueira, C. R., & Lopes, L. M. (2011). Antiplasmodial natural products. Molecules, 16, 2146–2190.
26. Memvanga, P. B., Tona, G. L., Mesia, G. K., Lusakibanza, M. M., & Cimanga, R. K. (2015). Antimalarial activity of medicinal plants from the Democratic Republic of Congo: A review. Journal of Ethnopharmacology, 169, 76–98.
27. Amoa Onguéne, P., Ntie-Kang, F., Lifongo, L. L., Ndom, J. C., Sippl, W., & Mbaze, L.Ma,. (2013). The potential of anti-malarial compounds derived from African medicinal plants. Part I: A pharmacological evaluation of alkaloids and terpenoids. Malaria Journal, 12, 449.
28. Ntie-Kang, F., Onguéne, P. A., Lifongo, L. L., Ndom, J. C., Sippl, W., & Mbaze, L.Ma,. (2014). The potential of anti-malarial compounds derived from African medicinal plants, part II: A pharmacological evaluation of non-alkaloids and non-terpenoids. Malaria Journal, 13, 81.
29. Muthaura, C., Keriko, J., Mutai, C., Yenesew, A., Gathiriwa, J., Irungu, B., Nyangacha, R., Mungai, G., & Derese, S. (2015). Antiplasmodial potential of traditional phytotherapy of some remedies used in treatment of malaria in Meru-Tharaka Nithi County of Kenya. Journal of Ethnopharmacology, 175, 315–323.
30. Omara, T. (2020). Antimalarial plants used across Kenyan communities. Evidence-Based Complement Alternative Medicine, 12, 4538602.
31. Manyo, M. H., Keymeulen, F., Ngezahayo, J., Bakari, A. S., Kalonda, M. E., Kahumba, B. J., Dzeg, P., Stévigny, C., & Lumbu, S. J. (2020). Antimalarial herbal remedies of Bukavu and Uvira areas in DR Congo: An ethnobotanical survey. Journal Ethnopharmacol, 249, 112422.
84. Habibi, P., De Sa, M. F. G., Makhzoum, A., Malik, S., da Silva, A. L. L., Hefferon, K., & Soccol, C. R. (2017). Bioengineering hairy roots: Phytoremediation, secondary metabolism, molecular pharming, plant-plant interactions and biofuels. In E. Lichtfouse (Ed.), Sustainable agriculture reviews (pp. 213–251). Cham: Springer International Publishing.

85. Habibi, P., Piri, K., Deljo, A., Moghadam, Y. A., & Ghasvand, T. (2015). Increasing Scopolamine content in hairy roots of atropa belladonna using bioreactor. Brazilian Archives of Biology and Technology, 58, 166–174.

86. Habibi, P., Soccol, C.R., Grossi-de-Sa, M.F. (2018). Hairy root activity in mammals of two typical plant glyco-epitopes, core α-L., Trottein, F., Faye, L., & Lerouge, P. (2003). Immunoreactivity of two typical plant glyco-epitopes, core α-L. in mammals. Journal of Biomedicine Human Vaccines, 13, 1169–1180.

87. Ali, M., Abbasi, B. H., Ahmad, N., Khan, H., & Ali, G. S. (2017). Strategies to enhance biologically active-secondary metabolites in cell cultures of Artemisia–current trends. Critical Reviews in Biotechnology, 37, 833–851.

88. Liu, C.-Z., Guo, C., Wang, Y., & Ouyang, F. (2003). Factors influencing artemisinin production from shoot cultures of Artemisia annua. World Journal of Microbiology and Biotechnology, 19, 535–538.

89. Patra, N., & Srivastava, A. K. (2015). Use of model-based nutrient feeding for improved production of artemisinin by hairy roots of Artemisia annua in a modified stirred tank bioreactor. Applied Biochemistry and Biotechnology, 177, 373–388.

90. Habibi, P., Soccol, C. R., O’Keefe, B. R., Krupme, L. R. H., Wilson, J., et al. (2018). Gene-silencing suppressors for high-level production of the HIV-1 entry inhibitor griffithsin in Nicotiana benthamiana. Process Biochemistry, 70, 45–54.

91. Arlen, P. A., Falconer, R., Cherukumilli, S., Cole, A., Cole, A. M., Oishi, K. K., & Daniel, I H. (2007). Field production and functional evaluation of chloroplast-derived interferon-alpha2b. Plant Biotechnol Journal, 5, 511–525.

92. Buyel, J., Twyman, R., & Fischer, R. (2017). Very-large-scale production of antibodies in plants: The biologization of manufacturing. Biotechnology Advances, 35, 458–465.

93. Holtz, B. R., Berquist, B. R., Bennett, L. D., Kommineni, V. J., Munigunti, R. K., White, E. L., et al. (2015). Commercial-scale biotherapeutics manufacturing facility for plant-made pharmaceutica. Plant Biotechnology Journal, 13, 1180–1190.

94. Riley, E. M., & Stewart, V. A. (2013). Immune mechanisms in malaria: New insights in vaccine development. Nature Medicine, 19, 168.

95. Laurens, M. B. (2018). The promise of a malaria vaccine—Are we closer? Annual Review of Microbiology, 72, 273–292.

96. Clemente, M., & Corigliano, M. G. (2012). Overview of plant made vaccine antigens against malaria. Journal of Biomedicine and Biotechnology, 2012, 8.

97. Farrance, C. E., Chichester, J. A., Musiychuk, K., Shamlou, M., Rhee, A., Manceva, S. D., et al. (2011). Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pf25 exhibit transmission blocking activity. Human Vaccines, 7, 191–198.

98. Sirraman, R., Bardor, M., Sack, M., Vaquero, C., Faye, L., Fischer, R., Finnen, R., & Lerouge, P. (2004). Recombinant anti-hCG antibodies retained in the endoplasmic reticulum of transformed plants lack core-xylose and core-α (1, 3)-fucose residues. Plant Biotechnology Journal, 2, 279–287.

99. Bardor, M., Faveeuw, C., Fitchette, A.-C., Gilbert, D., Galas, L., Trottein, F., Faye, L., & Lerouge, P. (2003). Immunoreactivity in mammals of two typical plant glyco-epitopes, core α (1, 3)-fucose and core xylose. Glycobiology, 13, 427–434.

100. Boes, A., Spiegel, H., Edgue, G., Kapelski, S., Scheuermann, M., Fendel, R., Remarque, E., Altmann, F., Maresch, D., & Reimann, A. (2015). Detailed functional characterization of glycosylated and nonglycosylated variants of malaria vaccine candidate Pf AMA 1 produced in Nicotiana benthamiana and analysis of growth inhibitory responses in rabbits. Plant Biotechnology Journal, 13, 222–234.

101. Glick, B. R., Patten, J. P. J., & Li, C. (2010). Molecular biotechnology: Principles and applications of recombinant DNA (4th ed.). John Wiley & Sons.

102. Gleba, Y. Y., Tuset, D., & Giritch, A. (2013). Plant viral vectors for delivery by Agrobacterium. In K. Palmer & Y. Gleba (Eds.), Plant viral vectors (pp. 155–192). Berlin Heidelberg: Springer.

103. Peyret, H., & Lomonossoff, G. P. (2015). When plant virology met Agrobacterium: The rise of the deconstructed clones. Plant Biotechnology Journal, 13, 1121–1135.

104. Giritch, A., Marillonnet, S., Engler, C., van Eldik, G., Botterman, J., Klimyuk, V., & Gleba, Y. (2006). Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proceedings of the National Academy of Sciences of the United States of America., 103, 14701–14706.

105. He, X., Haselhorst, T., von Itzstein, M., Kolarich, D., Packer, N. H., & Kermode, A. R. (2012). Influence of an ER-retention signal on the N-glycosylation of recombinant human alpha-L-iduronidase generated in seeds of Arabidopsis. Plant Molecular Biology, 79, 157–169.

106. Lai, H., & Chen, Q. (2012). Bioprocessing of plant-derived virus-like particles of Norwalk virus capsid protein under current good manufacturing practice regulations. Plant Cell Reports, 31, 573–584.

107. Poochcharoen, W., Bhoor, S. H., Lai, H., Ma, J., Arntzen, C. J., Chen, Q., & Mason, H. S. (2011). Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana. Plant Biotechnology Journal, 9, 807–816.

108. Webster, D. E., Wang, L., Mulcain, M., Ma, C., Santi, L., Mason, H. S., Wesseling, S. L., & Coppol, R. L. (2009). Production and characterization of an orally immunogenic Plasmodium antigen in plants using a virus-based expression system. Plant Biotechnol Journal, 7, 846–855.

109. O’Neill, K. M., Larsen, J. S., & Curtis, W. R. (2008). Scale-up of Agrobacterium-mediated transient protein expression in bioreactor-grown Nicotiana glutinosa plant cell suspension culture. Biotechnology Progress, 2, 372–376.

110. Fischer, R., Schillberg, S., Hellwig, S., Twyman, R. M., & Drossard, J. (2012). GMP issues for recombinant plant-derived pharmaceutical proteins. Biotechnol Advances, 30, 434–439.

111. Buyela, J. F. (2018). Plants as sources of natural and recombinant anti-cancer agents. Biotechnology advances, 36, 506–520.

112. Stoger, E., Fischer, R., Moloney, M., & Ma, J. K. C. (2014). Plant molecular pharming for the treatment of chronic and infectious diseases. Annual Reviews Plant Biology, 65, 743–768.

113. Spiegel, H., Boes, A., Voepel, N., Beiss, V., Edgue, G., Rademacher, T., Sack, M., Schillberg, S., Reimann, A., & Fischer, R. (2015). Application of a scalable plant transient gene expression platform for malaria vaccine development. Frontiers in Plant Science, 6, 1169.

114. Khan, I., & Daniell, H. (2021). Oral delivery of therapeutic proteins bioencapsulated in plant cells: Preclinical and clinical advances. Current Opinion in Colloid Interface Sciences, 54, 101452.

115. Davoodi-Semiromi, A., Schreiber, M., Nalapalli, S., Verma, D., Singh, N. D., Banks, R. K., et al. (2010). Chloroplastic-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery. Plant Biotechnology Journal, 8, 223–242.
116. Gregory, J. A., Topol, A. B., Doerner, D. Z., Mayfield, S. (2013). Algae-produced cholera toxin-Pfs25 fusion proteins as oral vaccines. Applied and Environmental Microbiology, 00714–00713.

117. Srinivasan, A., Herzog, R. W., Khan, L., Sherman, A., Bertolini, T., Wynn, T., et al. (2021). Preclinical development of plant-based oral immune-modulatory therapy for haemophilia B. Plant Biotechnology Journal, 10, 1952–1966.

118. Druilhe, P., Brandicourt, O., Chongsuphajaisiddhi, T., & Berthe, J.(1988). Activity of a combination of three cinchona bark alkaloids against Plasmodium falciparum in vitro. Antimicrobial agents and Chemotherapy, 32(2), 250–254. https://doi.org/10.1128/AAC.32.2.250

119. Elford, B. C., Roberts, M. F., Phillipson, J. D., & Wilson R. J. (1987). Potentiation of the antimalarial activity of quinina by methoxylated flavones. Transactions of the Royal Society of Tropical Medicine and Hygiene 81(3), 434–436.

120. Dwivedi, V., Khan, A., Vasco, A., Fatima, N., Soni, V. K., Dangi, A., Misra-Bhattacharya, S., & Owais, M. (2008). Immunomodulator effect of picroliv and its potential in treatment against resistant Plasmodium yoelii (MDR) infection in mice. Pharmaceutical Research, 25(10), 2312–2319.

121. Iwalokun, B. (2008). Enhanced antimalarial effects of chloroquine by aqueous Vernonia amygdalina leaf extract in mice infected with chloroquine resistant and sensitive Plasmodium berghei strains. African Health Sciences, 8(1), 25–35.

122. Mbacham, W. F., Njuabe, M. T., Evehe, M. S., Moyou, R., & Ekobo, A. (2005) Antimalarial drug studies in cameroon reveal deteriorating farsider and amoediaque cure rates. Journal of the Cameroon Academy of Sciences, 5, 58–63.

123. Delhaes, L., Abessolo, H., Biot, C., Berry, L., Delcourt, P., & Padmanaban, G. (2012). Production, characterisation and immunogenicity of a plant-made Plasmodium antigen—the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1. Applied Microbiology and Biotechnology, 94(1), 151–161. https://doi.org/10.1007/s00253-011-3772-7

124. Webster, D. E., Wang, L., Mulcair, M., Ma, C., Santi, L., Mason, H. S., Wesselingh, S. L. & Coppel, R. L. (2009). Production and characterization of an orally immunogenic Plasmodium antigen in plants using a virus-based expression system. Plant Biotechnology Journal, 7(9), 846–855. https://doi.org/10.1111/j.1476-7562.2009.00447.x

125. Ma, C., Wang, L., Webster, D. E., Campbell, A. E., & Coppel, R. L. (2012). Production, characterisation and immunogenicity of a plant-made Plasmodium antigen—the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1, a leading malaria vaccine antigen, in Arabidopsis thaliana seeds. Plant Biotechnology Journal, 8(9), 994–1004. https://doi.org/10.1111/j.1476-7562.2010.00526.x

126. Davoodi-Semiromi, A., Schreiber, M., Nalapalli, S., Verma, D., Singh, N. D., Banks, R. K., Chakrabarti, D., & Daniell, H. (2010). Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery. Plant Biotechnology Journal, 8(2), 223–242.

127. Lee, C., Kim, H. H., Mi Choi, K., Won Chung, K., Choi, Y. K., Jang, M. J., Kim, T. S., Chung, N. J., Rhee, H. G., Lee, H. S., & Sohn, Y. (2011). Murine immune responses to a Plasmodium vivax-derived chimeric recombinant protein expressed in Brassica napus. Malaria Journal, 10(1), 1–10. https://doi.org/10.1186/1475-2875-10-106

128. Farrance, C. E., Rhee, A., Jones, R. M., Musiyuchk, K., Sham-louli, M., Sharma, S., Mett, V., Chichester, J. A., Streftield, S. J., Roefwen, W., & van de Vege-Bolmer, M. (2011). A plant-produced Pfs25 vaccine candidate blocks transmission of Plasmodium falciparum. Clinical and Vaccine Immunology, 18(8), 1351–1357. https://doi.org/10.1128/CVI.05105-11

129. Jones, R. M., Chichester, J. A., Manceva, S., Gibbs, S. K., Musiyuchk, K., Sham-louli, M., Norikane, J., Streftield, S. J., van de Vege-Bolmer, M., Roefwen, W., & Sauerwein, R. W. (2015). A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses. Human Vaccines & Immunotherapeutics, 11(1), 124–132. https://doi.org/10.4161/hv.34366

130. Gregory, J. A., Li, F., Tomosada, C. L., Cox, C. J., Topol, A. B., Vinetz, J. M., & Mayfield, S. (2012). Algae-produced Pfs25 elicits antibodies that inhibit malaria transmission. PLoS One, 7(5), e37179. https://doi.org/10.1371/journal.pone.0037179

131. Beiss, V., Spiegel, H., Boes, A., Kapelski, S., Scheuermayer, M., Edgue, G., Sack, M., Fendel, R., Reimann, A., Schillberg, S., Ed...
S., & Pradel, G. (2015). Heat-precipitation allows the efficient purification of a functional plant-derived malaria transmission-blocking vaccine candidate fusion protein. Biotechnology and Bioengineering, 112(7), 1297–1305. https://doi.org/10.1002/bit.25548

143. Beiss, V., Spiegel, H., Boes, A., Scheuermayer, M., Reimann, A., Schillberg, S., & Fischer, R. (2015). Plant expression and characterization of the transmission-blocking vaccine candidate Pf GAP50. BMC Biotechnology, 15(1), 1–10. https://doi.org/10.1186/s12896-015-0225-x

145. Voepel, N., Boes, A., Edgue, G., Beiss, V., Kapelski, S., Reimann, A., Schillberg, S., Pradel, G., Fendel, R., Scheuermayer, M., & Spiegel, H. (2014). Malaria vaccine candidate antigen targeting the pre-erythrocytic stage of Plasmodium falciparum produced at high level in plants. Biotechnology Journal, 9(11), 1435–1445. https://doi.org/10.1002/biot.201400350

145. Boes, A., Spiegel, H., Voepel, N., Edgue, G., Beiss, V., Kapelski, S., Fendel, R., Scheuermayer, M., Pradel, G., Bolscher, J. M., & Behet, M. C. (2015). Analysis of a multi-component multi-stage malaria vaccine candidate—tackling the cocktail challenge. PloS One, 10(7), e0131456. https://doi.org/10.1371/journal.pone.0131456

146. Jones, R. M., Chichester, J. A., Mett, V., Jaje, J., Tottey, S., Manceva, S., Casta, L. J., Gibbs, S. K., Musiyuchuk, K., Shamoul, M., & Norikane, J. (2013). A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice. PloS One, 8(11), e79538. https://doi.org/10.1371/journal.pone.0079538

147. Gregory, J. A., Topol, A. B., Doerner, D. Z., & Mayfield, S. (2013). Alga-produced cholera toxin-Pfs25 fusion proteins as oral vaccines. Applied and Environmental Microbiology, 79(13), 3917–3925. https://doi.org/10.1128/AEM.00714-13

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.